Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Dublin, Feb. 16, 2018 -- The "Biosimilar Insulin Market Access" report has been added to ResearchAndMarkets.com's offering.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
EXECUTIVE SUMMARY
US
- Insights and strategic recommendations
- US payers are adopting a wait-and-see approach for biosimilar Basaglar
- Bibliography
FIVE MAJOR EU MARKETS
- Insights and strategic recommendations
- Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
- Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to
- reduce costs
- Payers use biosimilars to pressure originators on pricing
- Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
- Patient switching requires significant discounts of at least 30%
- Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
- Bibliography
METHODOLOGY
For more information about this report visit https://www.researchandmarkets.com/research/64x5p8/european_and_us?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Biosimilars and Biosuperiors
